LOGIN  |  REGISTER
Astria Therapeutics

LeMaitre Vascular Will Announce Second Quarter 2024 Earnings Results August 1, 2024

July 16, 2024 | Last Trade: US$92.12 0.13 -0.14

BURLINGTON, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its second quarter 2024 financial results on Thursday, August 1, 2024, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook.

Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor.

About LeMaitre

LeMaitre is a provider of devices, implants, and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Additional information can be found at www.lemaitre.com.

LeMaitre and the LeMaitre logo are registered trademarks of LeMaitre Vascular, Inc.

Viking Therapeutics

Stock Quote

Last Trade: US$92.12
Daily Change: -0.13 -0.14
Daily Volume: 367,631
Market Cap: US$2.070B

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB